AZTA Quote, Financials, Valuation and Earnings

Bionano Genomics has a net margin of -2.93% compared to Azenta's net margin of -728.57%. Azenta's return on equity of -7.49% beat Bionano Genomics's return on equity of -158.95%.

Azenta has a consensus price target of --, signalling upside risk potential of 13.13%. On the other hand Bionano Genomics has an analysts' consensus of -- which suggests that it could grow by 395.79%. Given that Bionano Genomics has higher upside potential than Azenta, analysts believe Bionano Genomics is more attractive than Azenta.

Azenta has a beta of 1.493, which suggesting that the stock is 49.318% more volatile than S&P 500. In comparison Bionano Genomics has a beta of 2.279, suggesting its more volatile than the S&P 500 by 127.944%.

Azenta has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bionano Genomics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Azenta pays -- of its earnings as a dividend. Bionano Genomics pays out -- of its earnings as a dividend.

Azenta quarterly revenues are $170.1M, which are larger than Bionano Genomics quarterly revenues of $6.1M. Azenta's net income of -$5M is higher than Bionano Genomics's net income of -$44.2M. Notably, Azenta's price-to-earnings ratio is -- while Bionano Genomics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Azenta is 4.06x versus 0.28x for Bionano Genomics. Usually stocks with elevated PS ratios are considered overvalued.

Bruker has a net margin of -2.93% compared to Azenta's net margin of 4.73%. Azenta's return on equity of -7.49% beat Bruker's return on equity of 19.61%.

Azenta has a consensus price target of --, signalling upside risk potential of 13.13%. On the other hand Bruker has an analysts' consensus of $74.01 which suggests that it could grow by 28.96%. Given that Bruker has higher upside potential than Azenta, analysts believe Bruker is more attractive than Azenta.

Azenta has a beta of 1.493, which suggesting that the stock is 49.318% more volatile than S&P 500. In comparison Bruker has a beta of 1.177, suggesting its more volatile than the S&P 500 by 17.733%.

Azenta has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bruker offers a yield of 0.35% to investors and pays a quarterly dividend of $0.05 per share. Azenta pays -- of its earnings as a dividend. Bruker pays out 6.88% of its earnings as a dividend. Bruker's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Azenta quarterly revenues are $170.1M, which are smaller than Bruker quarterly revenues of $864.4M. Azenta's net income of -$5M is lower than Bruker's net income of $40.9M. Notably, Azenta's price-to-earnings ratio is -- while Bruker's PE ratio is 27.59x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Azenta is 4.06x versus 2.62x for Bruker. Usually stocks with elevated PS ratios are considered overvalued.

Harvard Bioscience has a net margin of -2.93% compared to Azenta's net margin of -21.86%. Azenta's return on equity of -7.49% beat Harvard Bioscience's return on equity of -20.42%.

Azenta has a consensus price target of --, signalling upside risk potential of 13.13%. On the other hand Harvard Bioscience has an analysts' consensus of -- which suggests that it could grow by 197.62%. Given that Harvard Bioscience has higher upside potential than Azenta, analysts believe Harvard Bioscience is more attractive than Azenta.

Azenta has a beta of 1.493, which suggesting that the stock is 49.318% more volatile than S&P 500. In comparison Harvard Bioscience has a beta of 1.272, suggesting its more volatile than the S&P 500 by 27.217%.

Azenta has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Harvard Bioscience offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Azenta pays -- of its earnings as a dividend. Harvard Bioscience pays out -- of its earnings as a dividend.

Azenta quarterly revenues are $170.1M, which are larger than Harvard Bioscience quarterly revenues of $22M. Azenta's net income of -$5M is lower than Harvard Bioscience's net income of -$4.8M. Notably, Azenta's price-to-earnings ratio is -- while Harvard Bioscience's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Azenta is 4.06x versus 0.93x for Harvard Bioscience. Usually stocks with elevated PS ratios are considered overvalued.

Singular Genomics Systems has a net margin of -2.93% compared to Azenta's net margin of -4136.7%. Azenta's return on equity of -7.49% beat Singular Genomics Systems's return on equity of -54.24%.

Azenta has a consensus price target of --, signalling upside risk potential of 13.13%. On the other hand Singular Genomics Systems has an analysts' consensus of -- which suggests that it could fall by -35.36%. Given that Azenta has higher upside potential than Singular Genomics Systems, analysts believe Azenta is more attractive than Singular Genomics Systems.

Azenta has a beta of 1.493, which suggesting that the stock is 49.318% more volatile than S&P 500. In comparison Singular Genomics Systems has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Azenta has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Singular Genomics Systems offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Azenta pays -- of its earnings as a dividend. Singular Genomics Systems pays out -- of its earnings as a dividend.

Azenta quarterly revenues are $170.1M, which are larger than Singular Genomics Systems quarterly revenues of $406K. Azenta's net income of -$5M is higher than Singular Genomics Systems's net income of -$16.8M. Notably, Azenta's price-to-earnings ratio is -- while Singular Genomics Systems's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Azenta is 4.06x versus 17.93x for Singular Genomics Systems. Usually stocks with elevated PS ratios are considered overvalued.